Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mol Biol Rep. 2024 Jul 29;51(1):865. doi: 10.1007/s11033-024-09744-7.
Treating Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) is difficult due to high relapse rates and drug resistance. Tumorigenesis is largely dependent on disruption of the cell cycle progression. While the role of Cell Division Cycle 27 (CDC27) in the anaphase-promoting complex/cyclosome is well-known, its significance in the pathophysiology of acute leukemia and its potential as a biomarker are less well understood.
This case-control study used samples from 100 leukemia patients (50 with ALL and 50 with AML) at Shariati Hospital in Tehran, Iran, along with 50 healthy individuals. The expression of CDC27 was analyzed using quantitative real-time PCR (RQ-PCR). Statistical analysis was done using the nonparametric Mann-Whitney U test. The results showed that AML and ALL patients had significantly higher levels of CDC27 expression compared to the control group. Although a weak correlation between CDC27 expression and hematological parameters was found, there was no significant correlation with sample type, demographics, clinical variables or prognosis.
This study highlights the potential of CDC27 as an oncogene, as well as a possible prognostic and diagnostic marker in acute leukemias. It suggests that CDC27 could be a valuable biomarker or therapeutic target in the treatment of AML and ALL.
由于复发率高和耐药性，治疗急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）较为困难。肿瘤的发生在很大程度上依赖于细胞周期进程的破坏。虽然细胞分裂周期蛋白 27（CDC27）在后期促进复合物/周期蛋白中的作用是众所周知的，但它在急性白血病的病理生理学中的意义及其作为生物标志物的潜力还不太清楚。
本病例对照研究使用了来自伊朗德黑兰 Shariati 医院的 100 名白血病患者（50 名 ALL 和 50 名 AML）和 50 名健康个体的样本。使用实时定量 PCR（RQ-PCR）分析 CDC27 的表达。使用非参数 Mann-Whitney U 检验进行统计分析。结果表明，AML 和 ALL 患者的 CDC27 表达水平明显高于对照组。尽管发现 CDC27 表达与血液学参数之间存在微弱相关性，但与样本类型、人口统计学、临床变量或预后无显著相关性。
本研究强调了 CDC27 作为癌基因的潜力，以及在急性白血病中作为可能的预后和诊断标志物的潜力。它表明 CDC27 可能是 AML 和 ALL 治疗中的有价值的生物标志物或治疗靶点。
